Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine
Phase 3
Terminated
- Conditions
- CancerMucositis
- Registration Number
- NCT00224692
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Brief Summary
Hypothesis : Low dose ketamine has an analgesic effect in children with mucositis treated by patient-controlled analgesia with morphine
- Detailed Description
Double blind versus placebo multicenter Phase III trial of kétamine in children with chemotherapy induced-mucositis treated by patient-controlled analgesia with morphine
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Painful mucositis
- Child from 5 to 18 years.
- Presenting mucitis induced by chemotherapy or a conditioning of graft hematopoïetic.
- A pain not controlled by systematic paracetamol (10mg/kg/4h) or a the propacetamol (20mg/kg/4h).
- Not presenting a neurological or psychological difficulty at the use of the PCA or a EVA.
- First morphine amount going back to less 48h, and lass administration dating of more than 4h at the time of the beginning of the perfusion of Ketamine/placebo (EVA > 30 after stop morphine).
- Assent signed by the parents and each time possible by the child.
Exclusion Criteria
- The child was already included in the study.
- The age of psychomotor development is lower than 5 years
- Presence of a depression or a major depressive episode according to definition DSM IV.
- Hepatic or renal anomaly major (rank 3 or 4 of the scale of toxicity NCI CTC v2.0)
- Bilirubin>3N
- Gamma WP>3N
- SGOT or SGPT >5N
- Creatinin>3N
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Pain score
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain ketamine's analgesic effect in mucositis pain management?
How does low-dose ketamine compare to standard morphine PCA in pediatric mucositis pain control?
Are there specific biomarkers that predict ketamine response in chemotherapy-induced mucositis patients?
What are the potential adverse events associated with low-dose ketamine in children with cancer?
What combination therapies show promise for mucositis management alongside ketamine in Phase III trials?
Trial Locations
- Locations (1)
Hôpital Robert Debré Service Pédiatrie-Hémato-immunologie
🇫🇷Paris, Ile de France, France
Hôpital Robert Debré Service Pédiatrie-Hémato-immunologie🇫🇷Paris, Ile de France, France